Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · May 12, 2022

Efficacy and Safety of Dapagliflozin in Patients With T2DM According to Baseline Blood Pressure



Additional Info

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
Circulation 2022 May 05;[EPub Ahead of Print], RHM Furtado, I Raz, EL Goodrich, SA Murphy, DL Bhatt, LA Leiter, DK McGuire, JPH Wilding, P Aylward, AJ Dalby, M Dellborg, D Dimulescu, JC Nicolau, AJM Oude Ophuis, A Cahn, O Mosenzon, I Gause-Nilsson, AM Langkilde, MS Sabatine, SD Wiviott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading